BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27755376)

  • 1. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.
    Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T
    Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.
    Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C
    BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration.
    Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P
    Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
    Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
    Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
    Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
    Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
    Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
    Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Zhu M; Li H; Schlub TE; Wijeyakumar W; Chang AA
    Retina; 2015 May; 35(5):975-81. PubMed ID: 25627086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
    de Massougnes S; Dirani A; Mantel I
    Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
    Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
    Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
    Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
    Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
    Major JC; Wykoff CC; Croft DE; Wang R; Mariani AF; Lehmann AE; Brown DM
    Can J Ophthalmol; 2015 Oct; 50(5):373-7. PubMed ID: 26455973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of aflibercept in pigment epithelial detachments secondary to neovascular age related macular degeneration.
    Diaconita V; Li B; Pal L; Bahnacy F; Gonder JR
    Can J Ophthalmol; 2019 Oct; 54(5):626-634. PubMed ID: 31564356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal aflibercept in treatment-resistant pigment epithelial detachment.
    Kocak I
    Int Ophthalmol; 2017 Jun; 37(3):531-537. PubMed ID: 27444307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial.
    Hatz K; Prünte C
    Retina; 2017 Jun; 37(6):1185-1192. PubMed ID: 27652915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.